Pub Date : 2021-07-01DOI: 10.22141/2307-1257.10.2.2021.234322
Y. Yehudina, O. Dyadyk, S. A. Tripilka, S.Kh. Ter-Vartanіan
There is a complex bidirectional relationship between rheumatic diseases and cancer. Certain rheumatic diseases, in particular dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, and systemic sclerosis, on the one hand, are associated with an increased risk of malignant neoplasms against the background of the disease, contributing to cancer due to immunological stimulation. On the other hand, it can manifest as a result of autoimmune reactions caused by primary cancer in the form of paraneoplastic syndrome. Paraneoplastic syndrome is a symptom or set of symptoms that are secondary to the primary cancer process. These symptoms can result from substances secreted by the tumor (hormones and other biologically active substances) or due to the immune reaction to tumor cells (autoimmune reactions, the formation of immune complexes, suppression of the immune system), involving various organs and systems distant from the primary focus or metastases. This paper presents a literature review about the relationship between autoimmune diseases, to a greater extent systemic lupus erythematosus, and malignant neoplasms, and a clinical case in which the manifestation of lupus nephritis coincided with the detection of papillary thyroid carcinoma.
{"title":"Relationship between malignancies and autoimmunity. A literature review and analysis of a clinical case","authors":"Y. Yehudina, O. Dyadyk, S. A. Tripilka, S.Kh. Ter-Vartanіan","doi":"10.22141/2307-1257.10.2.2021.234322","DOIUrl":"https://doi.org/10.22141/2307-1257.10.2.2021.234322","url":null,"abstract":"There is a complex bidirectional relationship between rheumatic diseases and cancer. Certain rheumatic diseases, in particular dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, and systemic sclerosis, on the one hand, are associated with an increased risk of malignant neoplasms against the background of the disease, contributing to cancer due to immunological stimulation. On the other hand, it can manifest as a result of autoimmune reactions caused by primary cancer in the form of paraneoplastic syndrome. Paraneoplastic syndrome is a symptom or set of symptoms that are secondary to the primary cancer process. These symptoms can result from substances secreted by the tumor (hormones and other biologically active substances) or due to the immune reaction to tumor cells (autoimmune reactions, the formation of immune complexes, suppression of the immune system), involving various organs and systems distant from the primary focus or metastases. This paper presents a literature review about the relationship between autoimmune diseases, to a greater extent systemic lupus erythematosus, and malignant neoplasms, and a clinical case in which the manifestation of lupus nephritis coincided with the detection of papillary thyroid carcinoma.","PeriodicalId":17874,"journal":{"name":"KIDNEYS","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88481951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.22141/2307-1257.10.2.2021.234332
O. Iaremenko, D. Koliadenko
IgG4-related disease (IgG4-RD) is an immune-mediated fibro-inflammatory disease characterized by the formation of sclerotic tumor-like masses with dense lymphoplasmacytic infiltrates containing a significant number of IgG4-plasma cells. IgG4-RD is characterized by a wide range of clinical manifestations since the disease can involve almost any organ. Renal damage is observed in about 15 % of patients with IgG4-RD. The article presents a review of data about clinical manifestations of IgG4-related kidney disease (IgG4-RKD), specific features of diagnosis, and modern treatment approaches. The review of scientific publications was conducted in the international electronic scientometric database PubMed using keywords “IgG4-related kidney disease”, “IgG4-RKD radiographic findings”, “IgG4-related tubulointerstitial nephritis”, “IgG4-related membranous glomerulonephritis” over the period 2012–2020. The most common renal lesions in IgG4-RD are tubulointerstitial nephritis and membranous glomerulonephritis. They occur predominantly in older males. At the time of diagnosis, patients mostly already have concomitant extrarenal manifestations of IgG4-RD (sialadenitis, pancreatitis, lymphadenopathy). The clinical picture is usually vague, although nephrotic syndrome and chronic renal failure may occur. Typical manifestations of IgG4-RKD on CT are multiple low-dense foci, thickening of the renal pelvis, diffuse kidney enlargement. Renal involvement in IgG4-RD is often accompanied by low levels of complement. Early detection and treatment of IgG4-RKD are extremely important due to the increase in morbidity and mortality due to the development of chronic kidney disease. Glucocorticoids (GC) are first-line drugs for IgG4-RD. Despite a good response to GC, even a slight delay in treatment can lead to the development of renal tissue atrophy. The use of immunosuppressive drugs is advisable in cases when the dose of GC cannot be reduced due to the constantly high activity of the disease. Rituximab (a CD20+ B-lymphocyte inhibitor) may be used in patients with a recurrent course of IgG4-RKD.
{"title":"IgG4-related kidney disease","authors":"O. Iaremenko, D. Koliadenko","doi":"10.22141/2307-1257.10.2.2021.234332","DOIUrl":"https://doi.org/10.22141/2307-1257.10.2.2021.234332","url":null,"abstract":"IgG4-related disease (IgG4-RD) is an immune-mediated fibro-inflammatory disease characterized by the formation of sclerotic tumor-like masses with dense lymphoplasmacytic infiltrates containing a significant number of IgG4-plasma cells. IgG4-RD is characterized by a wide range of clinical manifestations since the disease can involve almost any organ. Renal damage is observed in about 15 % of patients with IgG4-RD. The article presents a review of data about clinical manifestations of IgG4-related kidney disease (IgG4-RKD), specific features of diagnosis, and modern treatment approaches. The review of scientific publications was conducted in the international electronic scientometric database PubMed using keywords “IgG4-related kidney disease”, “IgG4-RKD radiographic findings”, “IgG4-related tubulointerstitial nephritis”, “IgG4-related membranous glomerulonephritis” over the period 2012–2020. The most common renal lesions in IgG4-RD are tubulointerstitial nephritis and membranous glomerulonephritis. They occur predominantly in older males. At the time of diagnosis, patients mostly already have concomitant extrarenal manifestations of IgG4-RD (sialadenitis, pancreatitis, lymphadenopathy). The clinical picture is usually vague, although nephrotic syndrome and chronic renal failure may occur. Typical manifestations of IgG4-RKD on CT are multiple low-dense foci, thickening of the renal pelvis, diffuse kidney enlargement. Renal involvement in IgG4-RD is often accompanied by low levels of complement. Early detection and treatment of IgG4-RKD are extremely important due to the increase in morbidity and mortality due to the development of chronic kidney disease. Glucocorticoids (GC) are first-line drugs for IgG4-RD. Despite a good response to GC, even a slight delay in treatment can lead to the development of renal tissue atrophy. The use of immunosuppressive drugs is advisable in cases when the dose of GC cannot be reduced due to the constantly high activity of the disease. Rituximab (a CD20+ B-lymphocyte inhibitor) may be used in patients with a recurrent course of IgG4-RKD.","PeriodicalId":17874,"journal":{"name":"KIDNEYS","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76739442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.22141/2307-1257.10.2.2021.234321
D. Ivanov
The problem of detoxification therapy, in particular for kidney disease, is an important component of modern treatment. Renal dysfunction significantly complicates detoxification measures for at least two reasons. The first is to reduce the clearance of toxic substances, increase their content and redistribution in body tissues while reducing the glomerular filtration rate. The second reason is a change in the pharmacodynamics of detoxification drugs due to decreased renal function. Rheosorbilact is a hyperosmolar crystalloid electrolyte solution for infusion, which has detoxifying, rheological and alkalizing action with stimulation of intestinal motility. The drug is used to correct metabolic acidosis without causing sharp fluctuations in pH, due to the sodium lactate content, the effect of which manifested itself in 20–30 minutes after administration. Another important component of the drug is sorbitol, which in the form of an isotonic solution has a disaggregating effect, improving microcirculation and tissue perfusion. Sodium chloride in the drug replenishes the deficiency of sodium and chlorine ions, performing a rehydrating effect and increasing the volume of circulating blood, increasing diuresis, and calcium chloride replenishes the deficiency of calcium ions, reducing the permeability of the vascular wall and thus preventing the development of inflammatory reactions. The article presents a detailed analysis of the use of rheosorbilact with an emphasis on kidney disease and their function. Rheosorbilact can be used effectively and safely at a dose of 200 ml at a body weight of less than 60 kg and up to 400 ml at a body weight of more than 60 kg twice a day at an estimated glomerular filtration rate of more than 45 ml/min/m2 and no decompensated heart failure and stage III hypertension.
{"title":"Safety and effectiveness of rheosorbilact detoxification therapy in stage 1–3 CKD","authors":"D. Ivanov","doi":"10.22141/2307-1257.10.2.2021.234321","DOIUrl":"https://doi.org/10.22141/2307-1257.10.2.2021.234321","url":null,"abstract":"The problem of detoxification therapy, in particular for kidney disease, is an important component of modern treatment. Renal dysfunction significantly complicates detoxification measures for at least two reasons. The first is to reduce the clearance of toxic substances, increase their content and redistribution in body tissues while reducing the glomerular filtration rate. The second reason is a change in the pharmacodynamics of detoxification drugs due to decreased renal function. Rheosorbilact is a hyperosmolar crystalloid electrolyte solution for infusion, which has detoxifying, rheological and alkalizing action with stimulation of intestinal motility. The drug is used to correct metabolic acidosis without causing sharp fluctuations in pH, due to the sodium lactate content, the effect of which manifested itself in 20–30 minutes after administration. Another important component of the drug is sorbitol, which in the form of an isotonic solution has a disaggregating effect, improving microcirculation and tissue perfusion. Sodium chloride in the drug replenishes the deficiency of sodium and chlorine ions, performing a rehydrating effect and increasing the volume of circulating blood, increasing diuresis, and calcium chloride replenishes the deficiency of calcium ions, reducing the permeability of the vascular wall and thus preventing the development of inflammatory reactions. The article presents a detailed analysis of the use of rheosorbilact with an emphasis on kidney disease and their function. Rheosorbilact can be used effectively and safely at a dose of 200 ml at a body weight of less than 60 kg and up to 400 ml at a body weight of more than 60 kg twice a day at an estimated glomerular filtration rate of more than 45 ml/min/m2 and no decompensated heart failure and stage III hypertension.","PeriodicalId":17874,"journal":{"name":"KIDNEYS","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89125687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.22141/2307-1257.10.1.2021.227203
No Authors
No abstract
没有抽象的
{"title":"Energy and protein requirements for children with CKD stages 2–5 and on dialysis — clinical practice recommendations from the Pediatric Renal Nutrition Taskforce","authors":"No Authors","doi":"10.22141/2307-1257.10.1.2021.227203","DOIUrl":"https://doi.org/10.22141/2307-1257.10.1.2021.227203","url":null,"abstract":"No abstract","PeriodicalId":17874,"journal":{"name":"KIDNEYS","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77768619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.22141/2307-1257.10.2.2021.234319
M. Ivanova, A. Gozhenko, T. Crestanello, D. Ivanov
Parallel two-group prospective multicentre randomized trial named “HYD45 — Hydration in CKD 4–5 stages” that enrolled 62 patients with CKD G4–5 was aimed at evaluating of estimated glomerular filtration rate (eGFR) with coaching to increase water intake (CIWI) with the achievement of minimally higher diuresis by 400 mL in 31 patients compared with the CKD G4–5 group without CIWI. The stated duration was 12 months, and the trial was terminated in 6 months due to a more pronounced eGFR drop in the CIWI group, namely –3.3 ml vs. 2 ml in the group without CIWI. eGFR, renal functional reserve (RFR), albumin-to-creatinine ratio, and patient’s quality of life were additionally analyzed in this trial. Finally, three randomized clinical trials were analyzed in which patients with CKD 1–2, 3, and 4–5 received hydration. The results of studies demonstrate the possible efficacy of CIWI in stage 1–2 CKD in patients with normal or increased renal functional reserve. In stage 3 CKD, CIWI showed no benefits, and in stage CKD 4–5, forced hydration resulted in greater renal function loss. Summarizing these data, the authors concluded that it is probably appropriate for healthy people to consume the amount of fluid that provides physiological diuresis of 1.2–1.8 L and urine normal osmolarity. CIWI is often excessive, forced excessive hydration may not promote a healthy lifestyle. CIWI becomes forced excess hydration as kidney function decreases. Possibly, the benefits of CIWI are lost in CKD with the progression of renal function reduction. The effect of CIWI for 12 months may be positive for stage 1 CKD and stage 2 CKD with normal functional renal reserve. CIWI is probably impractical for chronic stages 3–5 CKD. In CKD 4–5, RFR is not preserved, which probably explains the negative effect of CIWI. With CKD G1, the CIWI leads to the optimal preservation of the renal function with the increase of GFR per 1 ml/min/1.73 m2 per year in comparison with the same water intake. In CKD G2, CIWI prevents physiological and pathological loss of renal function, RFR above 50 % provides restoration of eGFR in CKD G1–2. Early Coaching to Increase Water Intake in CKD (ECIWIC) trial demonstrates benefits of CIWI in patients with CKD G1–2 and preserved RFR and may be recommended to delay the CKD worsening.
{"title":"Coaching to increase water intake in CKD 1–5: overview and detailed analysis of three clinical trials","authors":"M. Ivanova, A. Gozhenko, T. Crestanello, D. Ivanov","doi":"10.22141/2307-1257.10.2.2021.234319","DOIUrl":"https://doi.org/10.22141/2307-1257.10.2.2021.234319","url":null,"abstract":"Parallel two-group prospective multicentre randomized trial named “HYD45 — Hydration in CKD 4–5 stages” that enrolled 62 patients with CKD G4–5 was aimed at evaluating of estimated glomerular filtration rate (eGFR) with coaching to increase water intake (CIWI) with the achievement of minimally higher diuresis by 400 mL in 31 patients compared with the CKD G4–5 group without CIWI. The stated duration was 12 months, and the trial was terminated in 6 months due to a more pronounced eGFR drop in the CIWI group, namely –3.3 ml vs. 2 ml in the group without CIWI. eGFR, renal functional reserve (RFR), albumin-to-creatinine ratio, and patient’s quality of life were additionally analyzed in this trial. Finally, three randomized clinical trials were analyzed in which patients with CKD 1–2, 3, and 4–5 received hydration. The results of studies demonstrate the possible efficacy of CIWI in stage 1–2 CKD in patients with normal or increased renal functional reserve. In stage 3 CKD, CIWI showed no benefits, and in stage CKD 4–5, forced hydration resulted in greater renal function loss. Summarizing these data, the authors concluded that it is probably appropriate for healthy people to consume the amount of fluid that provides physiological diuresis of 1.2–1.8 L and urine normal osmolarity. CIWI is often excessive, forced excessive hydration may not promote a healthy lifestyle. CIWI becomes forced excess hydration as kidney function decreases. Possibly, the benefits of CIWI are lost in CKD with the progression of renal function reduction. The effect of CIWI for 12 months may be positive for stage 1 CKD and stage 2 CKD with normal functional renal reserve. CIWI is probably impractical for chronic stages 3–5 CKD. In CKD 4–5, RFR is not preserved, which probably explains the negative effect of CIWI. With CKD G1, the CIWI leads to the optimal preservation of the renal function with the increase of GFR per 1 ml/min/1.73 m2 per year in comparison with the same water intake. In CKD G2, CIWI prevents physiological and pathological loss of renal function, RFR above 50 % provides restoration of eGFR in CKD G1–2. Early Coaching to Increase Water Intake in CKD (ECIWIC) trial demonstrates benefits of CIWI in patients with CKD G1–2 and preserved RFR and may be recommended to delay the CKD worsening.","PeriodicalId":17874,"journal":{"name":"KIDNEYS","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86520033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-01DOI: 10.22141/2307-1257.9.4.2020.218240
O. Dobryk, N. Lukianenko, M. Dushar
Against the background of an almost global pandemic of vitamin D deficiency, especially in childhood, it is necessary to sharpen the attention of doctors to conditions that are accompanied by hypervitaminosis D and severe disorders of phosphorus and calcium metabolism, which lead to dangerous consequences. These include idiopathic infantile hypercalcemia. Idiopathic infantile hypercalcemia is a rare hereditary autosomal recessive disease associated with impaired inactivation of active metabolites of vitamin D due to inactivating mutations in the CYP24A1 gene. The article describes a clinical case of hypervitaminosis D, hypercalcemia, hypoparathyroidism, the development of nephrocalcinosis in a young child against the background of inactivating mutations of the CYP24A1 gene.
{"title":"Idiopathic hypercalcemia in a child: a clinical case of hypervitaminosis and hypercalcemia in a young child","authors":"O. Dobryk, N. Lukianenko, M. Dushar","doi":"10.22141/2307-1257.9.4.2020.218240","DOIUrl":"https://doi.org/10.22141/2307-1257.9.4.2020.218240","url":null,"abstract":"Against the background of an almost global pandemic of vitamin D deficiency, especially in childhood, it is necessary to sharpen the attention of doctors to conditions that are accompanied by hypervitaminosis D and severe disorders of phosphorus and calcium metabolism, which lead to dangerous consequences. These include idiopathic infantile hypercalcemia. Idiopathic infantile hypercalcemia is a rare hereditary autosomal recessive disease associated with impaired inactivation of active metabolites of vitamin D due to inactivating mutations in the CYP24A1 gene. The article describes a clinical case of hypervitaminosis D, hypercalcemia, hypoparathyroidism, the development of nephrocalcinosis in a young child against the background of inactivating mutations of the CYP24A1 gene.","PeriodicalId":17874,"journal":{"name":"KIDNEYS","volume":"180 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80151212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-01DOI: 10.22141/2307-1257.9.4.2020.218235
D. Ivanov, O. Korzh
. Background. The purpose was to assess the efficacy and safety of Lactiale Uro, a product containing two strains of Lactobacilli plus cranberry extract and vitamin A, in preventing recurrent urinary tract infections (UTIs) in postmenopausal women (LACMUS study). Materials and methods . This was a randomized, prospective, multicenter study. Subjects received Lactiale Uro twice daily for 26 weeks after recovery from UTI; the control group didn’t receive the product. The primary endpoint was the proportion of subjects with recurrent UTI episodes at the end of the study. Results. Seventy-seven women were screened; 65 were enrolled; 61 completed the study. After 26 weeks, a significantly lower number of women experienced recurrent UTIs with Lactiale Uro compared to no treatment (9.7 vs 23.3 %; P < 0.05). Lactiale Uro produced statistically significant improvements, such as lower rates of UTI episodes (12.9 vs 36.6 %; P < 0.05); longer time to first UTI episode (136 vs 27 days; P = 0.0038); shorter duration of active UTI episode (5 vs 11 days; P = 0.0199); and shorter duration of antibacterial therapy for an active UTI episode (4 vs 10 days; P = 0.0462). Conclusions. Lactiale Uro was safe and effective for the prevention of recurrent UTIs in postmenopausal women. These data require further well-designed trials to clarify possible benefits.
{"title":"Laсtiale Uro in the prevention of postmenopausal urinary infection: LACMUS study results","authors":"D. Ivanov, O. Korzh","doi":"10.22141/2307-1257.9.4.2020.218235","DOIUrl":"https://doi.org/10.22141/2307-1257.9.4.2020.218235","url":null,"abstract":". Background. The purpose was to assess the efficacy and safety of Lactiale Uro, a product containing two strains of Lactobacilli plus cranberry extract and vitamin A, in preventing recurrent urinary tract infections (UTIs) in postmenopausal women (LACMUS study). Materials and methods . This was a randomized, prospective, multicenter study. Subjects received Lactiale Uro twice daily for 26 weeks after recovery from UTI; the control group didn’t receive the product. The primary endpoint was the proportion of subjects with recurrent UTI episodes at the end of the study. Results. Seventy-seven women were screened; 65 were enrolled; 61 completed the study. After 26 weeks, a significantly lower number of women experienced recurrent UTIs with Lactiale Uro compared to no treatment (9.7 vs 23.3 %; P < 0.05). Lactiale Uro produced statistically significant improvements, such as lower rates of UTI episodes (12.9 vs 36.6 %; P < 0.05); longer time to first UTI episode (136 vs 27 days; P = 0.0038); shorter duration of active UTI episode (5 vs 11 days; P = 0.0199); and shorter duration of antibacterial therapy for an active UTI episode (4 vs 10 days; P = 0.0462). Conclusions. Lactiale Uro was safe and effective for the prevention of recurrent UTIs in postmenopausal women. These data require further well-designed trials to clarify possible benefits.","PeriodicalId":17874,"journal":{"name":"KIDNEYS","volume":"2017 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82830297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-01DOI: 10.22141/2307-1257.9.4.2020.218237
No Authors
{"title":"KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","authors":"No Authors","doi":"10.22141/2307-1257.9.4.2020.218237","DOIUrl":"https://doi.org/10.22141/2307-1257.9.4.2020.218237","url":null,"abstract":"","PeriodicalId":17874,"journal":{"name":"KIDNEYS","volume":"103 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80768980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.22141/2307-1257.9.3.2020.211460
О. Volosovets, D. Ivanov, S. Kryvopustov, T. Borуsova, A. Volosovets
Оцінка впливу наслідків аварії на захворюваність та поширеність хвороб cечостатевої системи Abstract. Background . Over the past decades, the world has seen a significant increase in the prevalence and incidence of the genitourinary system diseases (GUSD) in children. The purpose of the study was to assess changes in the incidence and prevalence of diseases of the genitourinary system among the children population of Ukraine for the past 20 years in order to determine the possible impact of adverse environmental factors on their development, in particular the consequences of the Chernobyl accident and emis-sions from motor transport. Materials and methods . The analysis used the data of the State Institution “Center for Medical Statistics of the Ministry of Health of Ukraine” and the State Statistics Service of Ukraine for the period of 1997–2019. Methods of a sys-tematic approach, cluster, correlation and epidemiological analysis were used. Results . Over the past 20 years, there has been a 37.4% increase in the incidence rate of GUSD among Ukrainian children (0–17 years). Also, in recent years, the prevalence of this patho-logy has increased by 52.6 %. Children with the status of victims of the Chernobyl accident had a significant increase in the incidence of GUSD (by 70.7 %) compared to the national indicators of the incidence of GUSD in children. For the last 7 years, this rate has exceeded the national indicators and similar indicators for children permanently residing in regions that were not radioactively con-taminated as a result of the Chernobyl accident in 1986. Among children permanently residing in the regions of the country with territories of radiological control after the Chernobyl disaster, indicators of the incidence rates of diseases of the genitourinary system exceeded national ones in the early 90s and throughout the entire 20 years of monitoring. This fact requires continued monitoring of this cohort of children and taking the necessary medical and diag-nostic measures. Conclusions . The existing difference between the 20-year term incidence rates of diseases of the genitourinary system has shown higher incidence among children affected by the Chernobyl accident, and children from regions with territories of radiological control in comparison with other regions of Ukraine. This fact clearly indicates a possible correlation between frequency and prevalence of diseases of the genitourinary system in these groups of the children population and medical and environmental factors, including radiation.
{"title":"Assessment of the impact of the consequences of the Chernobyl accident on the incidence and prevalence of diseases of the genitourinary system in children of Ukraine","authors":"О. Volosovets, D. Ivanov, S. Kryvopustov, T. Borуsova, A. Volosovets","doi":"10.22141/2307-1257.9.3.2020.211460","DOIUrl":"https://doi.org/10.22141/2307-1257.9.3.2020.211460","url":null,"abstract":"Оцінка впливу наслідків аварії на захворюваність та поширеність хвороб cечостатевої системи Abstract. Background . Over the past decades, the world has seen a significant increase in the prevalence and incidence of the genitourinary system diseases (GUSD) in children. The purpose of the study was to assess changes in the incidence and prevalence of diseases of the genitourinary system among the children population of Ukraine for the past 20 years in order to determine the possible impact of adverse environmental factors on their development, in particular the consequences of the Chernobyl accident and emis-sions from motor transport. Materials and methods . The analysis used the data of the State Institution “Center for Medical Statistics of the Ministry of Health of Ukraine” and the State Statistics Service of Ukraine for the period of 1997–2019. Methods of a sys-tematic approach, cluster, correlation and epidemiological analysis were used. Results . Over the past 20 years, there has been a 37.4% increase in the incidence rate of GUSD among Ukrainian children (0–17 years). Also, in recent years, the prevalence of this patho-logy has increased by 52.6 %. Children with the status of victims of the Chernobyl accident had a significant increase in the incidence of GUSD (by 70.7 %) compared to the national indicators of the incidence of GUSD in children. For the last 7 years, this rate has exceeded the national indicators and similar indicators for children permanently residing in regions that were not radioactively con-taminated as a result of the Chernobyl accident in 1986. Among children permanently residing in the regions of the country with territories of radiological control after the Chernobyl disaster, indicators of the incidence rates of diseases of the genitourinary system exceeded national ones in the early 90s and throughout the entire 20 years of monitoring. This fact requires continued monitoring of this cohort of children and taking the necessary medical and diag-nostic measures. Conclusions . The existing difference between the 20-year term incidence rates of diseases of the genitourinary system has shown higher incidence among children affected by the Chernobyl accident, and children from regions with territories of radiological control in comparison with other regions of Ukraine. This fact clearly indicates a possible correlation between frequency and prevalence of diseases of the genitourinary system in these groups of the children population and medical and environmental factors, including radiation.","PeriodicalId":17874,"journal":{"name":"KIDNEYS","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74352876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.22141/2307-1257.9.3.2020.211463
No authors .
{"title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome","authors":"No authors .","doi":"10.22141/2307-1257.9.3.2020.211463","DOIUrl":"https://doi.org/10.22141/2307-1257.9.3.2020.211463","url":null,"abstract":"","PeriodicalId":17874,"journal":{"name":"KIDNEYS","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89476395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：